Literature DB >> 15357535

Clinical guidelines for the treatment of glaucoma.

Lawrence D Goldberg1.   

Abstract

Several documents guide screening and detection of glaucoma. The AAO guidelines are considered the current standard. The VA has established the need for regular screening based on identified factors. Finally, a task force working with NCQA to develop a glaucoma-related HEDIS measure may provide future direction in populationwide care.

Entities:  

Mesh:

Year:  2002        PMID: 15357535

Source DB:  PubMed          Journal:  Manag Care        ISSN: 1062-3388


  6 in total

1.  Unhealthy drinking patterns and receipt of preventive medical services by older adults.

Authors:  Elizabeth L Merrick; Dominic Hodgkin; Deborah W Garnick; Constance M Horgan; Lee Panas; Marian Ryan; Richard Saitz; Frederic C Blow
Journal:  J Gen Intern Med       Date:  2008-08-21       Impact factor: 5.128

Review 2.  Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2.

Authors:  Marcus Kernt; Aljoscha S Neubauer; Kirsten H Eibl; Armin Wolf; Michael W Ulbig; Anselm Kampik; Cristoph Hirneiss
Journal:  Clin Ophthalmol       Date:  2010-07-21

Review 4.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 5.  Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.

Authors:  Monique P Curran; Jennifer S Orman
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.